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Abstract
Erythropoetin-producing hepatoma (Eph) receptors are cell surface protein tyrosine kinases
mediating cell-cell communication. Upon activation they form signalling clusters. We report
crystal structures of the full ectodomain of human EphA2 (eEphA2), alone and in complex with
the receptor-binding domain of the ligand ephrinA5 (ephrinA5RBD). Unliganded eEphA2 forms
linear arrays of staggered parallel receptors involving two patches of residues conserved across A-
class Ephs. eEphA2-ephrinA5RBD forms a more elaborate assembly, whose interfaces include the
same conserved regions on eEphA2, but re-arranged to accommodate ephrinA5RBD. Cell surface
expression of mutant EphA2s demonstrated that these interfaces are critical for localization at cell-
cell contacts and activation-dependent degradation. Our results suggest a ‘nucleation’ mechanism
whereby a limited number of ligand-receptor interactions seed an arrangement of receptors which
can propagate into extended signalling arrays.
Ephs constitute a quarter of all known human receptor tyrosine kinases. They direct key
processes during development and repair of the nervous system, blood vessel formation,
insulin secretion, immune system function, intestinal homeostasis and bone tissue integrity1.
They are grouped into two classes, A and B2, but domain composition is conserved across
the family (Fig. 1a). The extracellular region comprises an N-terminal ligand-binding
domain (LBD), a cysteine-rich region and two fibronectin type III domains (FN1 and FN2).
FN2 connects to the transmembrane helix (TM), followed by an intracellular region
comprising a juxtamembrane region (JM), a tyrosine kinase domain and a sterile-alpha motif
(SAM) domain often linked to a C-terminal PDZ binding motif. Structures have been
determined for examples of all Eph domains in isolation, with the exception of the cysteine-
rich region3,4.
Activation of Eph receptors depends on the presence of their ligands (ephrins) and involves
the packing of Ephs into signalling clusters1,4. Ephrins consist of an N-terminal extracellular
receptor-binding domain (ephrinRBD) and a C-terminal extension linked to the plasma-
membrane by a lipid anchor (class A ephrins) or transmembrane helix (class B ephrins).
Binding affinities vary for different Eph-ephrin pairs, but in general binding within classes is
favoured5. Crystal structures for 1:1 complexes of Eph LBDs bound to ephrinRBDs show a
hydrophobic ephrin-binding groove on the receptor and provide insight into ligand-receptor
specificity, but do not define a mechanism for ligand-dependent signalling6. Members of the
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Eph family of receptor tyrosine kinases appear to require a more complex form of
oligomerisation to trigger signalling than the ligand-induced dimerisation model developed
from studies of systems such as the human growth hormone receptor7. Insights into Eph
receptor clustering upon ephrin binding are as yet limited4. The crystal structure of the
EphB2 LBD - ephrinB2RBD complex revealed a second, putative tetramerization, interface6.
However, five subsequent Eph LBD - ephrinRBD complex crystal structures have not shown
evidence for a consistent mode of oligomerisaton8-11. Biophysical and functional analyses
have also implicated additional regions of Eph ectodomains in ephrin mediated signalling12.
We therefore sought to provide structural insight into a full Eph receptor ectodomain
architecture and its interactions. We focus on EphA2 which is expressed during embryonic
development and in adult epithelia13 where it regulates cell adhesion14,15. EphA2 also acts
as a powerful oncogene in many tumours by promoting vascularisation and metastasis16-19.
RESULTS
Structure of EphA2 ectodomain (eEphA2)
To improve crystallization, we expressed eEphA2 (residues K27-N534) in glycosylation-
impaired mammalian cells20,21, trimmed the resultant glycans down to single N-
acetylglucosamine moieties and di-methylated the amino groups22. The structure (one
molecule per asymmetric unit) was refined to a final Rwork = 24% (Rfree = 30%) using data
to 3.0 Å resolution. Detailed data and refinement statistics are given in Table 1. A view of
the final electron density map is shown in Supplementary Fig. 1. All five domains are well-
ordered and the overall linear arrangement results in an elongated molecule (length ~172 Å,
width ~22-48 Å, Fig. 1b). The previously uncharacterized cysteine-rich region shows the
topology of a sushi (CCP) domain followed by an EGF-like domain. Sequence alignment of
class A Ephs mapped onto the eEphA2 structure reveals patches of surface conservation on
the LBD and sushi domains (Fig. 1c). Conserved sushi domain residues contribute to a
crystal contact with a parallel neighbouring molecule staggered by one domain (Fig. 1c). In
total, interfaces between these molecules bury 2661 Å2 of surface area and stabilise linear
arrays of staggered, parallel Ephs. These crystal contacts for full length EphA2 ectodomain
do not re-iterate the “head-to-head” contacts recently observed for crystals of EphA2
LBD10. Two putative N-linked glycosylation sites, located in the FN1 domain and in the
linker between domains FN1 and FN2, are not involved in crystal contacts.
Structure of eEphA2 in complex with ephrinA5RBD
To compare unliganded eEphA2 with a ligand-bound form, we attempted to crystallize it
with a panel of ephrinA ligands and succeeded in producing diffracting crystals of eEphA2
in complex with human ephrinA5 RBD (ephrinA5RBD). Di-methylation of the amine groups
and extensive optimization yielded a crystal (containing one eEphA2-ephrinA5RBD per
asymmetric unit) from which diffraction data were collected to 4.8 Å resolution. The
resultant complex structure was refined (by rigid body and TLS) to Rwork= 31%, Rfree= 31%
(Fig. 1d). Crystallographic details are summarized in Table 1 and an example of the final
electron density map is shown in Supplementary Fig. 1. The structure of ephrinA5RBD in the
complex shows no evidence of major structure changes when compared to the previously
reported structure23 of unliganded ephrinA5RBD. Superposition of ligand-bound and
unbound eEphA2s reveals domain re-orientations (Supplementary Fig. 2). The largest re-
orientation, a relative rotation of 71° by FN2, demonstrates the hinge-like character of the
FN1-FN2 linker. Other points of flexion are located between the LBD and sushi domain and
within the EGF-like domain.
The crystal consists of parallel and anti-parallel arrays of eEphA2-ephrinA5RBD complexes
(Supplementary Fig. 3) formed by interfaces A-F (Supplementary Fig. 4 and Supplementary
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Table 1). Interfaces A-E mediate parallel arrays (Fig. 1e and Fig. 2a), interface F stabilizes
anti-parallel packing (Fig. 2b). The previously reported Eph-LBD - ephrinRBD interaction3
forms interface A and broadly matches that previously reported for the complex of EphA2
LBD with ephrinA1RBD10 (Fig. 2a, c). Interface C is a small contact between eEphA2 and a
second ephrinA5RBD (Fig. 2a, c). Interfaces B, D and E connect neighbouring eEphA2
molecules via their LBDs, sushi domains and FN1 domains, respectively (Fig. 2a, c-e).
Interfaces B and D use the conserved surface patches which form the staggered LBD-sushi
contact in the unliganded eEphA2 crystals, but in the presence of ephrinA5RBD these
patches mediate in-register LBD-LBD (interface B) and sushi-sushi (interface D)
interactions (Fig. 1e). Finally, the FN1-FN2 domains from eEphA2 form interface F with
ephrinA5RBD bound (via interface A) to an anti-parallel eEphA2 neighbour (Fig. 2b, f).
EphA2 cell-cell contact localization is not dependent on the intracellular domains
Recent work has shown that EphA2 localizes at the cell-cell contacts in the mouse eye lens
where it binds to ephrinA5 and maintains tight cellular packing24. EphA2 is also known to
localize at cell-cell contacts when transfected into a range of epithelial cell lines25-27 and we
therefore chose to exploit this system to dissect the interaction characteristics of EphA2 in
vivo using a human embryonic kidney epithelial cell line (HEK293T) and fluorescent
protein (mVenus)-tagged constructs (Fig. 3). A series of deletion constructs all showed cell
surface expression (Supplementary Fig. 5). As anticipated, full length EphA2 accumulated
at the contact region between transfected cells. We did not observe EphA2 accumulation in
regions of the cell surface not involved in contacts, or in contact regions between EphA2-
expressing and non-transfected native cells (Fig. 3a-c). These observations imply that trans
presentation of EphA2 (i.e. from opposing cells) is required for clustering. We found that
deleting individual cytoplasmic domains, or the entire intracellular region, did not prevent
cell surface expression and did not affect the pattern of localization at cell-cell contacts
(Supplementary Fig. 6). In contrast, although cell surface localization is still maintained,
deletion of the N-terminal four extracellular domains (LBD-FN1) abolishes the specific
localization at the cell-cell interface, suggesting that the ectodomain is essential
(Supplementary Fig. 6).
Mutations in interfaces A, B, D, F affect cell-cell contact localization
To investigate which of the interfaces in our crystal structures have biological relevance, we
produced a panel of EphA2 point mutants designed to disrupt interfaces A-F
(Supplementary Table 1). Interface B and D mutations result in homogeneous EphA2 cell
surface distribution, completely abolishing the wild type localization pattern (Fig. 3d-f and
Supplementary Fig. 6). These are the major interfaces for the in-register arrays of liganded
eEphA2, the same surfaces form the staggered arrays for unliganded eEphA2, and in vivo
could mediate in cis interaction, i.e. of Eph receptors on the same cell. Previous mutagenesis
studies have indicated interface B residues can contribute to EphA3 – ephrinA5 binding
affinity12, although it is not the main ephrin binding site. Mutations in the minor interfaces
C and E had no effect on EphA2 localization (Supplementary Fig. 6).
Introduction of an N-linked glycosylation site (EphA2 A190N + L192S) to disrupt interface
A, the well-established ephrin binding site for binding in trans, abolished cell-cell contact
localization (Supplementary Fig. 6). As HEK293 cells express class A ephrins
endogenously28, these results suggest that binding to endogenous ephrins in trans is
necessary to drive localization of expressed EphA2 to cell-cell contacts, a conclusion further
supported by studies using insect (SF9) cells (Supplementary Fig. 6c). Interface F (the
second largest interface in the complex crystals) would in vivo be consistent with a cis-
interaction between ephrinA5 and EphA2 FN1-FN2; mutations at this interface caused an
intermediate phenotype where protein is partially de-localized over the entire cell surface
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(Supplementary Fig. 6). This is consistent with previous functional studies suggesting the
FN2 domain of EphA3 binds ephrinA5 in cis29.
Specific proteolytic cleavage of EphA2 depends on clustering
Previous studies have demonstrated that activation of Eph receptors leads to their
internalization and degradation30 and specific activation-dependent proteolytic cleavage has
been reported for EphB231,32. We performed immunoblot assays which show that EphA2 is
proteolytically cleaved in HEK293 cells. Upon wild type EphA2 expression at least three C-
terminal tyrosine-phosphorylated EphA2 proteolytic fragments are observed, corresponding
to ~70, ~75 and ~95 kDa (including the ~28 kDa mVenus tag, Supplementary Fig. 7). For
mutants in interfaces A, B and D the fragments of ~75 kDa and ~95 kDa are absent. For
mutants in interface F only the ~95 kDa fragment is absent. Notably, the cleavage patterns
observed for EphA2 wild type and mutants correlate with their cell surface localization
patterns; interface F mutants having less severe impairment of cell-cell contact localization
than interface A, B, and D mutants (Supplementary Fig. 6 and 7). The correlation of specific
cleavage with localization to cell-cell contacts suggests that this process depends on the
ability of the receptor to cluster via interfaces A, B, D and F.
DISCUSSION
Previously reported data for Eph function point to a requirement for receptor clustering into
extended cell surface assemblies4,33-35. However, full length Eph ectodomains (eEphA2,
eEphB2 and eEphB3) show no propensity to form oligomers in solution (as assessed by
multiple angle light scattering, MALS, and analytical ultracentrifugation) either alone or in
complex with monomeric, soluble ephrins (ephrinA5RBD, ephrinA2RBD and ephrinB2RBD)
(Supplementary Fig. 8 and data not shown). These data accord with previous reports that full
length Eph receptors only cluster if the ephrin ligand is presented in a membrane-bound or
oligomeric form36. Nevertheless, at very high concentration in crystals both unliganded and
complexed eEphA2 form array-like networks of interfaces which functional experiments
demonstrate are relevant to the cell surface signalling. The eEphA2 arrays involve staggered
interactions between the LBD and sushi domains. Ephrin binding snaps the Eph arrays into
register with LBD-LBD and sushi-sushi interactions involving the same eEphA2 surface
patches. Whilst we were completing our analysis an independently determined crystal
structure of unliganded human EphA2 ectodomain was deposited in the Protein Data Base37.
The 3FL7 lattice includes crystal contacts similar to the in-register form we observe
indicating that this mode of Eph-Eph interaction can also occur without ephrin-binding. This
implies that in the absence of ligand transient cis associations between cell surface Ephs
may occur as a dynamic equilibrium between LBD-LBD/sushi-sushi and LDB-sushi
interactions. For such a system ephrin-binding at “nucleation” points could trigger more
widespread recruitment of EphA2 into in-register arrays containing unliganded receptor and
facilitating, in a cooperative manner, additional ephrin-binding (Fig. 4).
Indeed, it has been reported that once an Eph receptor signalling cluster is nucleated by
ephrin-binding, further Eph are recruited to the cluster in an ephrin-independent manner33.
The above steric ‘seeding’ mechanism provides a model for how relatively low levels of
ephrins can trigger the formation of extended assemblies of EphA2. These assemblies may
be further stabilized by transmembrane38 and cytoplasmic39 region interactions. Our results
illustrate a nucleation mechanism for ectodomain-driven array-based signalling which could
be broadly applicable to other cell surface receptor systems.
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Secreted polyhistidine-tagged ectodomains of the human EphA2 (eEphA2, residues 27-534,
Uniprot: P29317) and ephrin A5 (ephrinA5RBD, residues 27-166, Uniprot: P52803) were
cloned into the AgeI-KpnI sites of pHLsec21 using standard PCR methods (EphA2 residues
1-23 and ephrinA5 residues 1-20 belong to the secretion signals in EphA2 and ephrin A5 as
predicted by SignalP40). For cell surface expression transmembrane constructs of human
EphA2, fused to a C-terminal monomeric fluorescent protein mVenus (green)41, were
cloned into pHLsec (coding additionally for a C-terminal poly-histidine tag). The following
constructs were produced as mVenus fusions: EphA2 (residues 27-976), EphA2ΔSAM
(residues 27-889), EphA2ΔKSAM (residues 27-564), EphA2Δe (residues 436-976). EphrinA5
(residues 27-166) was fused at its C-terminus to the monomeric transmembrane helix of
receptor protein tyrosine phosphatase RPTPμ42 (residues 742-769, Uniprot: P28827)
followed by the monomeric fluorescent protein mCherry, and cloned into pHLsec.
Protein Crystallization
Details of the protein expression and purification are given in the Supplementary Material
Online. eEphA2 was treated with endoglycosidase F143,44 and lysine-methylated 22.
Crystals diffracting to 3 Å resolution grew at 20 °C from drops45 where protein solution was
mixed 1:1:1 with reservoir solution (20 % polyethylene glycol 6000, 1 M LiCl, 0.1 M Tris
pH 8) and 0.4 M non-detergent sulfobetaine 256 (Hampton). Selenomethionine labeled
protein21 was purified and crystallized as the native protein. Crystals of eEphA2 and
ephrinA5RBD complex grew in conditions similar to the that specified below, but diffracted
only to 6-8 Å resolution. Only one crystal diffracted well to 4.8 Å resolution. This crystal
grew at 20 °C in a drop where two parts of protein solution were mixed with one part water,
one part reservoir solution (8 % polyethylene glycol 6000, 0.8 M LiCl, 0.08 M citrate pH 5)
and one part 1 % polyvinylpyrrolidone K15 (Hampton).
Data collection and processing
Data statistics are summarized in Table 1. Selenomethionine derivative crystals of eEphA2
were flash-frozen after briefly dipping the crystal containing loop into perfluoropolyether oil
PFO-X125/03 (Lancaster). A data set was collected at 100 K at the selenium edge
(wavelength = 0.98 Å) at the ESRF beamline BM14 using the inverse beam option (rotation
every 20 images, corresponding to 10 degrees). This crystal diffracted to 3 Å resolution. The
data were processed using XDS46 and MOSFLM47. Molecular replacement using models
for the ligand binding domain of EphA2 (PBD entry 3C8X), the fibronectin type III domain
2 of EphB4 (PDB entry 2E7H), and fibronectin type III domain 2 of EphA8 (PDB entry
1X5L) yielded initial phases that were used to locate selenium sites in PHASER48. Electron
density modification was done with DM49 and manual improvement of the protein model in
COOT50. Cycles of phase calculation plus model building and refinement iteratively lead to
a satisfactory model. A second crystal yielded better data at high resolution at the ESRF
beamline ID23-EH2 (100 K, wavelength = 0.87 Å) and was used for the final rounds of
refinement. eEphA2 carries two predicted N-glycosylation sites, the first is on the FN1
domain where N-acetyl-glucosamine (NAG) was placed into the electron density. This NAG
molecule is in close proximity to, but not in contact with the FN2 domain of a neighbouring
EphA2 chain. The second putative N-glycosylation site located in the poorly defined linker
region between FN1 and FN2 and lacked electron density indicating the presence of sugar,
possibly due to the relative disorder of this region. This region is also not involved in crystal
contacts. COOT and MOLPROBITY51 were used for model validation. 3 residues (0.6 %)
are located in outlier regions of the Ramachandran plot.
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Crystals of eEphA2 in complex with ephrinA5RBD were frozen in a cryoprotectant solution
containing one part reservoir solution and one part reservoir solution supersaturated with
LiCl. After brief equilibration in cryoprotectant, the crystals were mounted on a loop which
was then dipped into perfluoropolyether oil PFO-X125/03 and flash-frozen. The best dataset
was collected at 100 K on ESRF beamline ID14-EH2 (wavelength = 0.93 Å) and processed
using XDS. A model of human EphA2 ligand binding domain in complex with ephrin A2
receptor binding domain (PDB code 3CZU) was used for molecular replacement in
PHASER (RFZ=11.1, TFZ=9.6, LLG=162). We placed the models of individual eEphA2
domains sequentially into the improving density and refined each using rigid body
refinement in PHASER. Molecular replacement was initially done using the 3.0 Å resolution
eEphA2 model presented here. After deposition of the 2.5 Å resolution eEphA2 model in the
Protein Data Bank (PBD code 3FL7) by the Structural Genomics Consortium, Toronto, we
used this higher resolution model. The model was refined using PHENIX52 (Supplementary
Material Online). 6 residues are in outlier regions of the Ramachandran plot as found in the
input molecular replacement model downloaded from the Protein Data Bank. The two
putative N-glycosylation sites lie outside crystal contact areas.
To calculate the angle between the orientations eEphA2 FN2 adopts in the unliganded and
ephrinA5RBD-bound structures, we first generated two models of liganded eEphA2
superposed onto the FN1 and FN2 domains of unliganded eEphA2. We then used LSQKAB
within the CCP4 suite53 to calculate the rotation applied to superpose the two resulting
structures via their FN2 domain.
Multiangle Light Scattering (MALS)
Proteins were purified by size-exclusion chromatography and concentrated to approximately
1.6 ml/ml (eEphA2) and 1.8 mg/ml (eEphA2/ephrinA5RBD complex). Separation for the
MALS was achieved using an analytical Superdex S75 10/30 column (GE Heathcare) and
the eluate was passed through online static light scattering (DAWN HELEOS II, Wyatt
Technology, Santa Barbara, CA), differential refractive index (Optilab rEX, Wyatt
Technology) and Agilent 1200 UV (Agilent Techologies) detectors. Data were analysed
using the ASTRA software package (Wyatt Technology).
Live cell assays
HEK293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM high
glucose, Sigma) supplemented with L-glutamine, non-essential amino-acids (Gibco) and
10% foetal calf serum (FCS, Sigma). Plasmid DNA was transfected with lipofectamine 2000
following the recommended protocol (Invitrogen). Final concentrations were 2 μg plasmid
DNA per ml, 5 μl lipofectamine per ml and 1.5% FCS. After 4-6 hours, cells were returned
to growth medium, which contains 10% FCS, and plated on poly-L-lysine-coated glass
bottom culture plates (MatTek). To observe trans interactions of different constructs, cells
were transfected separately and plated out together at this stage. 15-20 hours later cells were
imaged using a Zeiss LSM510 confocal microscope (with variable emission detectors
[Meta-Head]). For this time-scale, we do not observe cell-rounding and death upon EphA2
expression for either HEK293 or COS7 cells (data not shown). All images were taken with
the same detector and laser settings and the images showing fluorescent signal were not
subsequently modified, thus allowing direct comparison.
Immunoblot analysis
To assess cell surface expression of truncated EphA2 constructs, cells were incubated for 10
minutes at 4 °C to slow down endocytosis and then incubated 30 min with 1 mg/ml No-
Weigh Sulfo-NHS-LC-Biotin (Pierce) at 4 °C. The biotinylation reaction was stopped by
adding 100 mM Tris pH 7.5. Cells were lysed in phosphate buffer saline supplemented with
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100 mM Tris pH 7.5 and 1% Triton X-100 (Sigma). Cell lysates were incubated for 30
minutes with streptavidin-coated agarose beads (Pierce) at 4 °C, the beads washed three
times with lysis buffer and then re-suspended in standard protein denaturing gel loading
buffer for immunoblot analysis using anti-pentahistidine (penta-His, Qiagen, dilution
1:1000). Cells intended for anti-phosphotyrosine or anti-green fluorescent protein
immunoblot analyses were re-suspended in chilled phosphate buffer saline 15-20 hours post
transfection, immediately mixed with standard protein gel loading buffer and analyzed using
anti-phosphotyrosine (4G10® Platinum, Millipore, dilution 1:2000), anti-GFP (Cat. No.
A-11122, Invitrogen, dilution 1:1000), anti-actin (ACTN05 (C4), AbCam, dilution 1:400),
anti-mouse IgG peroxidase-conjugated secondary antibody (Sigma, dilution 1:10000) and
anti-rabbit IgG peroxidase-conjugated secondary antibody (AbCam, dilution 1:5000). To
rule out that FCS or trace amounts of trypsin used for cell propagation are responsible for
EphA2 cleavage, we performed control experiments in cells cultured with 0% or 1.5% FCS,
in the presence of 0%, 0.5% or 5% of the trypsin-EDTA solution used for tissue culture
maintenance (Invitrogen, Cat. No. 25300-054) (data not shown).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Crystal structures of the complete EphA2 extracellular region (eEphA2) alone and in
complex with ephrinA5RBD
a, Domain composition of ephrinAs and Eph receptors. b, Crystal structure of eEphA2
comprising EphA2 LBD, Cys, FN1 and FN2 domains. Colours are as in a. The previously
uncharacterized Cys domain is composed of a sushi domain (CCP) and an EGF domain. c,
Arrangement of two eEphA2 molecules within the crystal. Their contacts bury 2661 Å2 of
molecular surface. The front molecule is displayed and oriented as in a. The back molecule
is shown in surface view and coloured according to human Eph class A receptor sequence
conservation (red = strongest conservation, white = weakest conservation). d, eEphA2
(colours as in a) in complex with ephrinA5RBD (cyan). The orientation of the sushi domain
is the same as in b and c. e, Arrangement of neighbouring complexes within the crystal. The
eEphA2 molecule on the right is oriented and coloured as in d. Its neighbour on the left is in
surface view and coloured according to EphA2 sequence conservation. Their contacts bury
1240 Å2.
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Figure 2. The eEphA2-ephrinA5RBD complex: structural changes within eEphA2 and formation
of array-like clusters
a, b, Crystal packing of eEphA2-ephrinA5RBD. The ribbon diagrams are coloured as in Fig.
1. The cartoon above each panel illustrates the crystal contacts designated interfaces A-F
(dotted lines) for eEphA2 (purple) and ephrinA5RBD (cyan). Panel a shows six symmetry-
related eEphA2-ephrinA5RBD complexes forming a parallel array; view is approximately
along unit cell axis c. The protein arrangement reflects EphA2 and ephrinA5 interaction in
trans, i.e. where the proteins are located on opposing cells. Panel b shows six symmetry-
related eEphA2-ephrinA5RBD complexes forming an anti-parallel array, view as in f, but
tilted by ~45° around unit cell axis a. The arrangement shows EphA2 and ephrinA5
interacting both in trans and in cis, consistent with both proteins presented on both cells. c-f,
Interfaces A-F are shown as black lines. Colours are as in a. Interfaces A-E form the crystal
contact interactions shown in a, interface F is a major interface but contributes only to the
contacts shown in b.
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Figure 3. EphA2 localization at cell-cell contacts depends on ectodomain clustering
Representative results are presented of functional studies using HEK293T cells. A full set of
results is provided in Supplementary Fig. 6. Filled white arrows indicate cell-cell contacts
between transfected cells. Open arrows point to cell-cell contacts between a transfected cell
and a non-transfected cell. a-c, mVenus-tagged EphA2 accumulates at cell-cell contacts of
transfected cells. d-e, Mutants in interfaces A, B, D and, to some extent, interface F do not
cluster at cell-cell contacts of transfected cells but are distributed evenly on the cell surface
(the interface B mutant G131Y is shown as an example). a, d Fluorescence images are
shown. b, e, Phase contrast images of the corresponding cells. c, f, Overlay images of a, b, d,
e.
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Fig.4. A mechanism for the nucleation and propagation of EphA2 signalling assemblies
a, b, Eph and ephrin are shown schematically with ectodomains colour coded as in Fig. 1a
and the Eph intracellular region in grey. Lightening flashes indicate the strength of
activation. In panel a transient arrays of staggered Ephs snap into in-register signalling
arrays on nucleation by ephrins. The intermediate phenotype of interface F mutations in
functional assays may reflect weaker interactions between Eph receptors and their ligands,
resulting in a weakened signalling activity. In panel b additional cis (interface F) interactions
inter-connect anti-parallel arrays further stabilising the signalling assemblies.
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Table 1
Data collection and refinement statistics
eEphA2 (refinement) eEphA2 (phasing) eEphA2+ephrinA5RBD
Data collection
RCSB PDB code XXX XXX XXX
Space group P1 P1 P2221
Cell dimensions











Resolution (Å)* 46-3.0 (3.1-3.0) 45-3.0 (3.1-3.0) 173.6-4.8 (4.9-4.8)
Rmeas * 0.143 (0.443) 0.097 (0.645) 0.112 (0.743)
I/σI* 9.87 (2.60) 8.97 (1.74) 12.95 (2.83)
Completeness (%)* 97.6 (94.5) 97.8 (97.7) 98.2 (75.5)
Redundancy* 3.3 (2.3) 2.2 (2.0) 6.2 (6.3)
Refinement
Resolution (Å)* 45.9-3.0 (3.3-3.0) - 40.5-4.8 (6.1-4.8)
No. reflections 12037 - 5643
Rwork/Rfree 0.236/0.299 - 0.312/0.314
No. atoms 3743 - 4889
 Protein 3728 - 4889
 Ligand/ion 15 - -
 Water - - -
average B-factors
 Protein 100.4 - 247.2
 Ligand/ion 107.6 - -
 Water - - -
R.m.s. deviations
 Bond lengths (Å) 0.004 - 0.003
 Bond angles (°) 0.697 - 0.675
*Values in parentheses are for highest-resolution shell.
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